<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421222</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-7386-CS-001</org_study_id>
    <nct_id>NCT04421222</nct_id>
  </id_info>
  <brief_title>Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>EPI-7386</acronym>
  <official_title>A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ESSA Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ESSA Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, clinical research study of EPI-7386, an investigational drug being studied&#xD;
      as a treatment for patients with prostate cancer. All patients in the study will receive&#xD;
      EPI-7386.&#xD;
&#xD;
      Since this is the first study of EPI-7386 in humans, there is no information about how it&#xD;
      affects people or what dose should be used. Therefore, the main purpose of this study is to&#xD;
      assess the safety (side effects) of EPI-7386 and to find a dose that can be given without&#xD;
      unacceptable side effects.&#xD;
&#xD;
      There are other important things that will be evaluated during the study:&#xD;
&#xD;
        -  How the amount of EPI-7386 in the blood changes over time.&#xD;
&#xD;
        -  The effect of EPI-7386 on prostate cancer.&#xD;
&#xD;
        -  The effect of EPI-7386 on certain substances in the body.&#xD;
&#xD;
        -  The possibility that EPI-7386 can interact with other drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety variable for Part 1a of the study is the incidence of protocol-defined DLT during the DLT assessment period (first 28 days of dosing).</measure>
    <time_frame>5 months</time_frame>
    <description>The DLTs will be characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for AEs [NCI CTCAE version 5.0]), timing, seriousness, and relationship to study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The primary efficacy variable for Part 1b of the study is the proportion of patients with a decline from baseline in PSA blood concentrations of â‰¥50% at any time point during daily dosing with EPI-7386.</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg EPI-7386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg EPI-7386</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-7386 (QD)</intervention_name>
    <description>Once daily oral dose of EPI-7386</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-7386 (BID)</intervention_name>
    <description>Twice daily oral dose of EPI-7386</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male 18 years of age or older.&#xD;
&#xD;
          -  Histologically, pathologically, or cytologically confirmed prostate cancer without&#xD;
             small cell features.&#xD;
&#xD;
          -  Evidence of castration-resistant prostate cancer (CRPC).&#xD;
&#xD;
          -  Presence of metastatic disease at study entry documented by 1 or more bone lesions on&#xD;
             bone scan or by soft tissue disease observed by CT/MRI.&#xD;
&#xD;
          -  No further treatment options available known to confer clinical benefit in this&#xD;
             disease setting from the perspective of the treating physician (maximum 3 prior&#xD;
             approved systemic therapies for mCRPC).&#xD;
&#xD;
          -  Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3&#xD;
             (PCWG3) criteria.&#xD;
&#xD;
          -  The patient must have recovered from toxicities related to any prior treatments.&#xD;
&#xD;
          -  Castrate at screening.&#xD;
&#xD;
          -  Patients receiving bisphosphonates or other approved bone-targeting therapy must be on&#xD;
             a stable dose for at least 4 weeks prior to the start of study drug.&#xD;
&#xD;
          -  Demonstrate adequate organ function.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Biologic anti-cancer therapy or a cytotoxic chemotherapy within 4 weeks prior to the&#xD;
             start of study drug.&#xD;
&#xD;
          -  Use of hormonal agents with anti-tumor activity against prostate cancer within 4 weeks&#xD;
             prior to the start of study drug.&#xD;
&#xD;
          -  Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs&#xD;
             within 14 days or 5 half-lives, whichever is longer, of the first dose of study drug.&#xD;
&#xD;
          -  Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days&#xD;
             prior to the start of study drug.&#xD;
&#xD;
          -  Received limited-field palliative bone radiotherapy &gt;5 fractions and/or any&#xD;
             radiotherapy within 2 weeks prior to the start of study drug.&#xD;
&#xD;
          -  Received a blood transfusion within 28 days of screening.&#xD;
&#xD;
          -  Known intra-cerebral disease or brain metastasis unless adequately treated and stable&#xD;
             for the last 4 weeks before enrollment.&#xD;
&#xD;
          -  Spinal cord compression.&#xD;
&#xD;
          -  Diagnosis of another invasive malignancy within the previous 3 years other than&#xD;
             curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma.&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption.&#xD;
&#xD;
          -  Significant cardiovascular disease.&#xD;
&#xD;
          -  Concurrent disease or any clinically significant abnormality.&#xD;
&#xD;
          -  Use of compounds known to be strong inducers and strong inhibitors of CYP3A and CYP2C8&#xD;
             within 14 days of the first dose of study drug.&#xD;
&#xD;
          -  Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and&#xD;
             CYP2B6.&#xD;
&#xD;
          -  Presence of metastasis to soft-tissue other than lymph nodes.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Villaluna</last_name>
    <phone>650-449-8400</phone>
    <email>kvillaluna@essapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of NV Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

